Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Hydralazine hydrochloride
Drug ID BADD_D01082
Description Originally developed in the 1950s as a malaria treatment, hydralazine showed antihypertensive ability and was soon repurposed.[A186841] Hydralazine is a hydrazine derivative vasodilator used alone or as adjunct therapy in the treatment of hypertension and only as adjunct therapy in the treatment of heart failure.[A186820,L8782,L8785] Hydralazine is no longer a first line therapy for these indications since the development of newer antihypertensive medications.[T691] Hydralazine hydrochloride was FDA approved on 15 January 1953.[L8779]
Indications and Usage Hydralazine is indicated alone or adjunct to standard therapy to treat essential hypertension.[L8782] A combination product with isosorbide dinitrate is indicated as an adjunct therapy in the treatment of heart failure.[L8785]
Marketing Status approved
ATC Code C02DB02
DrugBank ID DB01275
KEGG ID D01302
MeSH ID D006830
PubChem ID 9351
TTD Drug ID D0K1XK
NDC Product Code 58032-1004; 68259-1313; 51079-076; 55150-400; 55154-5689; 67877-292; 71872-7268; 72241-004; 72241-006; 75834-127; 75834-128; 17478-934; 31722-520; 31722-522; 43353-124; 50090-4641; 63629-8493; 63629-8494; 71209-017; 72572-265; 31722-521; 50228-183; 50228-184; 51079-074; 55154-7294; 63629-8495; 63629-8496; 63739-327; 70518-2551; 71209-016; 72241-005; 55154-9554; 62584-734; 63187-901; 67877-290; 70934-764; 71872-7145; 75834-126; 68259-1307; 69037-0047; 23155-002; 50228-182; 51079-075; 51662-1388; 55154-7293; 55154-7295; 62135-582; 62584-733; 0404-9994; 70518-0666; 70518-0832; 70934-571; 71205-091; 71335-1589; 0615-7973; 71872-7274; 76282-312; 55512-0010; 39822-0500; 50090-0137; 50228-185; 62135-579; 63629-8757; 63739-328; 64380-736; 67877-291; 71205-072; 71335-0482; 71335-1236; 0641-6231; 76282-311; 77771-184; 77771-185; 0904-6442; 62350-0080; 77777-116; 23155-004; 50090-0139; 50111-327; 50111-398; 51662-1376; 55154-6628; 63323-614; 64380-733; 64380-734; 0517-0901; 70518-1685; 71610-562; 59651-148; 66039-957; 72643-001; 31722-519; 43353-205; 50111-328; 55154-2082; 63629-5246; 63629-8497; 68071-2530; 68788-8087; 70518-0637; 71209-018; 71335-1685; 71335-9722; 71610-549; 71610-561; 76282-310; 0904-6441; 17511-102; 55289-133; 62135-581; 64380-735; 67544-657; 71335-0594; 71872-7050; 77771-182; 0904-6440; 0904-6443; 49452-3544; 23155-001; 43063-392; 50111-397; 61919-312; 62135-580; 63629-5696; 67877-293; 0404-9986; 68071-5285; 68084-447; 71335-0202; 76282-309; 77771-183; 65691-0088; 68554-0023; 23155-003; 55154-2083; 55154-5085
UNII FD171B778Y
Synonyms Hydralazine | Hydrallazin | Hydrazinophthalazine | Apressin | Nepresol | Hydralazine mono-Hydrochloride | Hydralazine mono Hydrochloride | mono-Hydrochloride, Hydralazine | Apressoline | Apresoline | Hydralazine Hydrochloride | Hydrochloride, Hydralazine
Chemical Information
Molecular Formula C8H9ClN4
CAS Registry Number 304-20-1
SMILES C1=CC=C2C(=C1)C=NN=C2NN.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Paraesthesia17.02.06.005; 23.03.03.094--
Pruritus23.03.12.001--
Purpura24.07.06.005; 23.06.01.004; 01.01.04.003--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Red blood cell count decreased13.01.05.007--Not Available
Splenomegaly01.09.02.001--Not Available
Tachycardia02.03.02.007--Not Available
Tremor17.01.06.002--
Urticaria23.04.02.001; 10.01.06.001--
Vomiting07.01.07.003--
Decreased appetite14.03.01.005; 08.01.09.028--
Blood disorder01.05.01.004--Not Available
Psychotic disorder19.03.01.002--
The 2th Page    First    Pre   2    Total 2 Pages